Open AccessDifferences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy
Author(s) -
Wilkoff Bruce L.,
Birnie David,
Gold Michael R.,
Hersi Ahmad S.,
Jacobs Sandra,
Gerritse Bart,
Kusano Kengo,
Leclercq Christophe,
Mullens Wilfried,
Filippatos Gerasimos
Publication year - 2020
Publication title -
esc heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 25
ISSN - 2055-5822
DOI - 10.1002/ehf2.12914
Subject(s) - medicine , cardiac resynchronization therapy , heart failure , left bundle branch block , qrs complex , randomized controlled trial , cardiology , quality of life (healthcare) , population , cardiomyopathy , clinical trial , physical therapy , ejection fraction , nursing , environmental health
Aims Response to cardiac resynchronization therapy (CRT) is known to be associated with a number of clinical characteristics, including QRS duration and morphology, gender, height, and the aetiology of heart failure (HF). We assessed the relation of gender and baseline characteristics with QRS duration and Kansas City Cardiomyopathy Questionnaire. Methods and results AdaptResponse is a global randomized trial. The trial enrolled CRT‐indicated patients with New York Heart Association classes II–IV HF, left bundle branch block (QRS ≥ 140 ms in men, ≥130 ms in women), and baseline PR interval ≤200 ms. In total, 3620 patients were randomized, including 1569 women (43.3%) approaching the actual proportion of women in the HF population. Women were older and more often New York Heart Association class III or IV than men (55.6% vs. 48.7%), had less frequent ischaemic cardiomyopathy (21.2% vs. 39.5%), and had a 5.1 ms shorter QRS duration than men. Women were more often depressed (18.5% vs. 9.7%), had a significantly lower Kansas City Cardiomyopathy Questionnaire score, and had differences in medication prescriptions. Conclusions AdaptResponse is the largest randomized CRT trial and enrolled more women than any other landmark CRT trial. Women differed from men with regard to baseline characteristics and quality of life. Whether these differences translate into clinical outcome differences will be examined further in the AdaptResponse trial.